Rapid communication · 29 May 2025
Review articlePublished 28 Feb 2023
Suspension vs Conventional Pump Therapy for Hypoglycemic Unaware Patients with Type 1 Diabetes
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In patients with type 1 diabetes who lack awareness of hypoglycaemia, the objective was to compare the cost-effectiveness of sensor-augmented insulin pump therapy with "Low Glucose Suspend" (LGS) functionality to standard pump therapy with self-monitoring of blood glucose. Methods: The net costs and effectiveness of the two treatment options were calculated and expressed as an incremental cost-effectiveness ratio (ICER) in an economic evaluation based on a clinical trial. The rate of severe hypoglycaemia in each LGS study arm was the clinical outcome of interest for the evaluation. Personal satisfaction utility scores were determined utilizing the three-level EuroQol five-layered survey. Costs associated with resource use were estimated using public data. Results: At six months, compared to standard pump therapy, the use of sensor-augmented insulin pump therapy with LGS significantly reduced the incidence of severe hypoglycaemia (incident rate difference 1.85 [0.17–3.53]); P = 0.037). The ICER per severe hypoglycaemic event avoided was $18,257 for all patients in a primary randomized study and $14,944 for patients over the age of 12. The ICERs were $17,602 and $14,289, respectively, when all major medical resource costs (like hospital admissions) were taken into account. For patients over the age of 12, the cost per quality-adjusted life-year gained over the course of the six months was $40,803. Conclusions: In type 1 diabetes patients who are unaware of their hypoglycaemia, sensor-augmented insulin pump therapy with LGS may be considered a cost-effective alternative to standard pump therapy with selfmonitoring of blood glucose. This is based on the Australian experience evaluating new interventions across a wide range of therapeutic areas. Keywords Cost-effectiveness; Hypoglycaemia; Insulin pump therapy; Type 1 diabetes
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Diabetes & Metabolism.
Rapid communication · 29 May 2025
Genetic and epigenetic markers for gdm risk
Short communication · 29 May 2025
Metabolic syndrome: Diet, timed eating, supplements
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Diabetes & Metabolism
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Tim Jones”